Introduction
Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients.
Methods
We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed.
Results
Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug.
Conclusion
In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
【저자키워드】 Immunosuppression, Remdesivir, Acute kidney injury, Kidney transplantation, SARS-CoV2l, 【초록키워드】 COVID-19, Treatment, Efficacy, coronavirus, mechanical ventilation, randomized trial, Diagnosis, Toxicity, antiviral activity, Kidney injury, adverse events, Cohort, adverse event, Patient, age, Time to recovery, Admission, patients, kidney transplant, kidney transplant recipient, kidney transplant recipients, noninvasive, Safe, median time, younger patients, renal, multicenter cohort study, Result, resulting, reported, diagnosed, required, treated, demonstrated, adults hospitalized, systemic symptom, were assessed, with COVID-19, 【제목키워드】 COVID-19, Safety, Transplant, recipient,